Best Oncology Companies in Australia
The 90 best Oncology companies in Australia in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Kazia Therapeutics.
Ranked by disclosed equity funding and recent momentum, the 90 Oncology companies we're tracking across Australia have pulled in $802M in total disclosed capital, with no unicorns yet but a pipeline that's clearly building pressure. Kazia Therapeutics leads at $86M, followed by Clarity Pharmaceuticals and OncoSil Medical at $28M each, and Ena Respiratory at $25M. The global market sits at roughly $250.9B in 2025 and is forecast to reach $668.3B by 2034 at an 11.5% CAGR, driven by precision medicine expansion and rising cancer incidence. Cost-containment policies are the structural friction worth watching, but they haven't slowed deal flow globally, as Zydus's move on Assertio signals just how aggressively players are positioning right now.
So what's moving in Australia specifically? Coverage is flat, but the hot themes, cancer biomarkers, angiogenesis inhibitors, and AI's growing role in oncology genetics, are exactly where the local pipeline skews. Investors like Artesian, Brandon Capital, and Uniseed are the names you'll see backing the most active bets here. The funding is concentrated but the scientific range is genuinely broad.
- Oncology R&D: emerging therapies and new challenges
Our analysis of 50 Oncology companies
$16.3b in tracked funding; 86% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Oncology companies in Australia
| # | Company | Disclosed funding | Last round | Employees | Founder | Stage | Market signals (1y) | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Kazia Therapeutics Developer of small molecules for the treatment of cancer | $86M | 6 mo ago | 9 | — | Public | — | 3 patents Novel functionalized benzopyran compounds for therapeutic drug development | 1 expansion · 1 award |
| 2 | Viralytics Developing oncolytic virotherapy treatments for a range of cancers such as Melanoma, bladder cancer. | $83M | 101 mo ago | 6 | — | Acquired | — | 59 patents Oncolytic virus-based cancer therapies and combination immuno‑stimulatory treatments | — |
| 3 | Pharmaxis Developer of drugs for inflammatory and fibrotic diseases | $68M | 46 mo ago | 93 | Gary Phillips CEO | Public | — | 145 patents Small-molecule lysyl oxidase and amine oxidase inhibitors for therapeutic use | — |
| 4 | Immutep Developer of immunotherapies for the treatment of cancer and autoimmune diseases | $66M | 60 mo ago | 35 | Marc Voigt CEO | Acquired | — | — | — |
| 5 | ImmVirX Developer of immunotherapy for cancer treatment | $47M | 36 mo ago | 16 | Malcolm McColl Co-Founder & CEO | Series B | — | — | — |
| 6 | Radiopharm Theranostics Manufacturer of radiopharmaceutical products for diagnostic test | $46M | 22 mo ago | — | Paul Hopper Executive Chairman & Founder | Public | 4 signals Earnings · Leadership · Funding | — | — |
| 7 | Clinical Genomics Biomarker-based blood tests for early cancer detection | $41M | 96 mo ago | 50 | Susanne Pedersen Co-Founder & CSO | Deadpooled | — | 256 patents Colorectal cancer epigenetic methylation biomarker panels for diagnostic testing | — |
| 8 | Immuron Developer of oral immunotherapy utilizing polyclonal antibody products | $37M | 71 mo ago | 6 | Jerry Kanellos CEO | Public | 5 signals Earnings · New product | 79 patents Bovine hyperimmune colostrum therapeutics for bacterial and viral gastrointestinal infections | 1 launch |
| 9 | Clarity Pharmaceuticals Developer of drugs to treat cancer | $28M | 10 mo ago | 41 | — | Public | — | 129 patents Targeted radiopharmaceuticals for prostate and neuroendocrine cancer imaging and therapy | — |
| 10 | OncoSil Medical Developer of a medical device for the treatment of pancreatic cancer | $28M | 12 mo ago | 2 | Daniel Kenny Chief Executive Officer | Public | — | 7 patents Patents concentrated in health & consumer products | 1 partnership |
| 11 | EnGeneIC Developer of targeted anti-cancer therapies using nanocell platform technology | $25M | 110 mo ago | 30 | — | Series B | — | — | — |
| 12 | Ena Respiratory Developer of antiviral host defense enhancers for respiratory infections. | $25M | 8 mo ago | 9 | Christophe Demaison Managing Director | Series B | — | 38 patents Lipid-based TLR2 agonist immunostimulants for treating respiratory infections and allergies | — |
| 13 | Telix Pharma Developer of theranostic radiopharmaceuticals for imaging and treating cancer | $25M | 67 mo ago | 234 | — | Public | 40 signals Earnings · Lawsuit · Regulatory | — | 1 partnership · 1 award |
| 14 | Arovella Therapeutics Developer of cell therapies to treat cancer and neurological diseases | $23M | 17 mo ago | 44 | — | Public | — | 2 patents Repurposing anagrelide for cancer therapy, especially metastatic thrombocytotic cancers | — |
| 15 | ChemGenex Pharmaceuticals Specialty company developing oncology drugs | $21M | 231 mo ago | 6 | — | Acquired | — | 16 patents Homoharringtonine-based therapies for kinase‑inhibitor‑resistant chronic myeloid leukemia | — |
| 16 | Chimeric Therapeutics Provider of CAR T cell therapies for solid tumors | $21M | 20 mo ago | 19 | Paul Hopper Executive Chairman & Founder | Public | — | — | 1 award |
| 17 | Noxopharm Developer of drugs for the treatment of cancer and septic shock | $18M | 26 mo ago | 17 | — | Public | — | 65 patents Isoflavone-derived pharmaceutical compounds for cancer immunotherapy and infection‑related inflammation | 2 launchs · 1 partnership |
| 18 | AdvanCell Radiopharmaceutical company developing targeted alpha therapies for cancer treatment | $17M | 14 mo ago | 23 | Andrew Adamovich Founder | Series C | — | — | 1 expansion |
| 19 | Exopharm Developer of exosome-based therapeutics for targeted treatments | $12M | 62 mo ago | 39 | — | Public | — | 30 patents Exosome isolation/purification reagents and fluorescent labeling dyes for biomedical research | — |
| 20 | Carina Biotech Provider of immunotherapies for the treatment of cancer | $11M | 46 mo ago | 17 | Justin Coombs Managing Director | Series A | — | 24 patents Ovarian cancer diagnostics/therapies and CAR‑T cell immunotherapy manufacturing technologies | 1 partnership · 1 award |
| 21 | Cartherics Developer of cellular immunotherapy for cancer | $10M | 20 mo ago | — | Ian Nisbet Co-Founder and Chief Operating Officer | Series B | — | — | 2 awards |
| 22 | Currus Biologics Developer of CAR-T cell therapies for solid tumors | $10M | 59 mo ago | 5 | Sam Cobb CEO | Series A | — | 16 patents Engineered bispecific antibodies and polypeptides for rescuing exhausted immune cells | 1 launch |
| 23 | Ferronova Provider of magnetic probe based device of treatment of multiple cancer | $9M | 6 mo ago | 10 | — | Series A | — | — | — |
| 24 | Minomic Non-invasive blood tests for cancer | $8M | 114 mo ago | 14 | Brad Walsh Founder & CEO | Series A | — | — | — |
| 25 | Haemalogix Developer of immunotherapies for blood cancers and autoimmune diseases | $7M | 57 mo ago | 8 | — | Series A | — | 23 patents Therapeutic peptides and antibody-based drugs targeting myeloma antigens. | — |
| 26 | INOVIQ Developer of a portfolio of diagnostic and exosome-based products for the diagnosis and treatment of cancer | $6M | 8 mo ago | 5 | Leearne Hinch CEO | Public | — | 4 patents Polymer resin formulations and extracellular vesicle-based therapeutic/diagnostic technologies. | — |
| 27 | TruScreen Cervical cancer screening device | $4M | 111 mo ago | — | — | Public | 3 signals Earnings | — | 1 partnership · 1 expansion |
| 28 | Adalta Developing next-generation antibody therapeutics for the treatment of fibrosis and cancer. | $3M | 25 mo ago | 12 | — | Public | — | 18 patents Therapeutic biologics targeting CXCR4, RANKL, and malaria antigen binding proteins | 3 partnerships |
| 29 | Prescient Therapeutics Targeted small molecule inhibitors of Ras and Akt pathway for the treatment of cancer | $3M | 69 mo ago | 1 | Wayne Millen CEO | Public | — | 16 patents Engineered universal immune cell platforms for adoptive cell and gene therapies | — |
| 30 | Rhythm Biosciences Developer diagnostic tests for the detection of cancer | $3M | 24 mo ago | — | David Atkins Chief Executive Officer | Public | — | — | 1 partnership |
| 31 | Imugene Developer of a therapeutic vaccine for the treatment of cancer | $2M | 17 mo ago | 5 | Leslie Chong CEO & MD | Public | — | 15 patents Therapeutic cancer vaccines and oncolytic virus platforms for immune activation | — |
| 32 | Beroni Group Developer of cell therapies for treating cancer | $2M | 32 mo ago | 65 | Jacky Zhang CEO | Public | — | — | — |
| 33 | PredicTx Health Developer of a platform for personalized chemotherapy dosing using body analysis | $2M | 8 mo ago | — | Justin Yeung Co-Founder & CMO | Seed | — | — | — |
| 34 | Cyteph Developer of CAR T cell therapies for the treatment of cancer | $2M | 36 mo ago | — | Rajiv Khanna Founder and CSO | Funding Raised | — | — | — |
| 35 | Patrys Specialty company developing products for treatment of cancer | $2M | 45 mo ago | 23 | James Campbell CEO and Managing Director | Public | — | 90 patents Therapeutic monoclonal antibodies and epitope-based biologics targeting LM‑1 for oncology and metabolic applications | — |
| 36 | Immune System Therapeutics Monoclonal antibodies (MAbs) to treat cancers and autoimmune diseases | $700K | 255 mo ago | — | Rosanne Dunn Co-Founder | Deadpooled | — | 18 patents Therapeutic antibodies and biologics for treating B‑cell mediated immune disorders | — |
| 37 | Respiratory Innovations Medical procedures for monitoring breathing functions and guidance | $400K | 116 mo ago | — | Sean Pollock COO & Co-Founder | Deadpooled | — | — | — |
Top 12 Oncology companies in Australia
#1
Public · Sydney, New South Wales · founded 1994 · 9 employees$85.7Mraised▾
Developer of small molecules for the treatment of cancer. The lead product Paxalisib is a small molecule inhibitor of the PI3K / Akt / mTOR pathway which regulates growth and cell division is used for the treatment of glioblastoma, DIPG, CNS lymphoma, and brain metastases. Another drug VT801 is a small molecule inhibitor of VEGFR3, which helps in the development of new blood vessels and lymphatic vessels in a growing tumour.
- Dec 2025Post IPO$55.3M
- Aug 2025Post IPO$2.1M
- Jan 2023Post IPO$3.1M
- Oct 2020Post IPO$11.8M
#2
Series B · Melbourne, Victoria · founded 2020 · 9 employees$25Mraised▾
{}
- Oct 2025Series B$22.4M
- Feb 2025Series B$5M
- Jun 2021Series B$25M
#3
Series A · Salisbury, South Australia · founded 2016 · 10 employees$9.1Mraised▾
Ferronova provides a magnetic probe-based device of treatment of multiple cancer. The device is patented and composed of iron and iron oxide nanoparticles for treating head, neck, breast cancer, and melanoma. It is a tracer system and ultra-sensitive magnetometer which helps in lymph node identification, which helps in cancer treatment and identification of nodes injection site.
- Dec 2025Series A$6M
- Jan 2023Series A$5.6M
- Jan 2023Grant (prize money)$2.1M
- Apr 2020Series A$3.5M
#4
Public · Sydney, New South Wales · founded 2010 · 41 employees$28.1Mraised▾
Developer of drugs to treat cancer. The company utilizes radiopharmaceutical technology for developing targeted therapies. The company has developed drug candidates used for the neuroendocrine tumour, neuroblastoma, colorectal, glioma, and prostate diseases. The company has also developed programs for companion diagnostics in the preclinical stage.
- Jul 2025Post IPO$133.3M
- Mar 2024Post IPO$79M
- Dec 2020Series B$25M
- Jun 2016Grant (prize money)$2.5M
#5
Public · Sydney, New South Wales · founded 2005 · 2 employees$27.8Mraised▾
Developer of a medical device for the treatment of pancreatic cancer. The company's flagship product includes OncoSil which is a brachytherapy device used for the treatment of pancreatic cancer. It is used to deliver beta radiation to the cancerous tissue by causing direct damage to the cancer cell DNA. The device contains proprietary diluent that acts as a carrier to implant the microparticles of radioisotope (phosphorous-32) to the targeted cell.
- May 2025Post IPO$8.7M
- Apr 2022Post IPO$10M
- Feb 2016Post IPO$7.1M
- 2005Post IPO$2M
#6
Public · Notting Hill, Victoria · founded 1983 · 5 employees$6.1Mraised▾
Developer of a portfolio of diagnostic and exosome-based products for the diagnosis and treatment of cancer. The company has an hTERT test used as an adjunct to urine cytology testing for bladder cancer and the EXO-NET pan-exosome capture tool for research purposes.
- Oct 2025Post IPO$6.1M
#7
Series C · Brisbane, Queensland · founded 2019 · 23 employees$17.4Mraised▾
Radiopharmaceutical company developing targeted alpha therapies for cancer treatment. The company involves a proprietary ²¹²Pb production technology that provides access to alpha isotopes to accelerate the clinical development of drugs for prostate, skin, pancreatic, breast, bladder, colorectal, kidney, lung, and ovary cancer.
- Apr 2025Grant (prize money)$18M
- Feb 2025Series C$112M
- Dec 2023Series B$5M
- Aug 2022Series B$12.4M
#8
Public · Perth, Western Australia · founded 1999 · 44 employees$23Mraised▾
Developer of cell therapies to treat cancer and neurological diseases. The company is focusing on the development of a natural killer T (iNKT) cell therapy platform for the treatment of human diseases. ZolpiMist is a first-in-class oral spray of zolpidem tartrate to treat short-term insomnia. The company is developing other products to treat migraine, headaches, motion sickness, blood cancers, malignant tumors, and drug-resistant epilepsy.
- Jan 2025Post IPO$20M
- Jan 2022Post IPO$3M
#9
Public · Carlton, Victoria · founded 2021$45.8Mraised▾
Manufacturer of radiopharmaceutical products for diagnostic test
- Jul 2024Post IPO$45.8M
- Feb 2024Post IPO—
#10
Seed · Melbourne, Victoria · founded 2025$1.6Mraised▾
Developer of a platform for personalized chemotherapy dosing using body analysis. The platform analyzes CT scans to segment muscle, fat, bone, and tumor volume. This creates a detailed body composition profile for each patient. Machine learning models then predict the optimal chemotherapy dose before the first cycle.
- Oct 2025Seed$1.6M
#11
Public · Carlton, Victoria · founded 2020 · 19 employees$20.8Mraised▾
Provider of CAR T cell therapies for solid tumors. The company offers its proprietary clinical-stage CLTX-CART technology that includes chlorotoxin (CLTX), which is a peptide obtained from scorpion toxin, which targets the CAR-T cell in solid tumors.
- Oct 2024Post IPO$3.4M
- Jun 2023Post IPO$10.1M
- Feb 2022Post IPO$7.4M
#12
Series B · Notting Hill, Victoria · founded 2014$10.4Mraised▾
Developer of cellular immunotherapy for cancer. The company has developed their technology platform combined with stem cells and immunotherapy (gene-modified antigen-specific T cell and chimeric antigen receptor technology) which helps in genetic enhancement of cytotoxic killer T cells and provides dual cancer binding receptors. It is used to treat cancers like relapsed ovarian cancer and gastric cancers.
- Oct 2024Series B$10.4M
- Sep 2022Grant (prize money)$3.6M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Oncology coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Oncology & Cancer Therapeutics is moving in Australia
A read on the academic research around Oncology & Cancer Therapeutics — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 1,017 Australia-affiliated papers.
- University College London121
- Ludwig Cancer Research115
- The University of Queensland85
- Peter MacCallum Cancer Centre73
- Monash University70
- Tumor microenvironment14→125
- Immunotherapy2→101
- Cancer research12→98
- Immune system8→91
- Cancer immunotherapy1→73
- Tumor microenvironment15→206
- Immune system11→145
- Immunotherapy11→133
- Cancer research19→104
- Cancer immunotherapy5→60
- Immunotherapy8→74
- Tumor microenvironment4→57
- Immune system7→53
- Cancer immunotherapy5→30
- Cancer research4→25
Where oncology is researched across Australia
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.